Motor, cognitive, and functional declines contribute to a single progressive factor in early HD
- 12 December 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 89 (24) , 2495-2502
Abstract
Objective: To identify an improved measure of clinical progression in early Huntington disease (HD) using data from prospective observational cohort studies and placebo group data from randomized double-blind clinical trials. Methods: We studied Unified Huntington Disease Rating Scale (UHDRS) and non-UHDRS clinical measures and brain measures of progressive atrophy in 1,668 individuals with early HD followed up prospectively for up to 30 to 36 months of longitudinal clinical follow-up. Results: The results demonstrated that a composite measure of motor, cognitive, and global functional decline best characterized clinical progression and was most strongly associated with brain measures of progressive corticostriatal atrophy. Conclusions: Use of a composite motor, cognitive, and global functional clinical outcome measure in HD provides an improved measure of clinical progression more related to measures of progressive brain atrophy and provides an opportunity for enhanced clinical trial efficiency relative to currently used individual motor, cognitive, and functional outcome measures.Keywords
This publication has 19 references indexed in Scilit:
- A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's diseaseMovement Disorders, 2013
- Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Indexing disease progression at study entry with individuals at‐risk for Huntington diseaseAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011
- Huntington's disease: from molecular pathogenesis to clinical treatmentThe Lancet Neurology, 2011
- Signal-to-noise ratio (SNR) as a measure of reproducibility: design, estimation, and applicationHealth Services and Outcomes Research Methodology, 2008
- Riluzole in Huntington's disease: a 3‐year, randomized controlled studyAnnals of Neurology, 2007
- A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s diseaseNeurology, 2001
- Unified Huntington's disease rating scale: Reliability and consistencyMovement Disorders, 1996
- A controlled clinical trial of baclofen as protective therapy in early huntington's diseaseAnnals of Neurology, 1989
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982